CONTACT
+91 80 2808 2808
info@biocon.com
About Us
Overview
Who we are
Our Key Priorities
Board of Directors
Key Management Team
Our Legacy
Fact Sheet
Our Stories
Awards & Recognition
Products
Overview
Key Therapeutic Areas
Generics
Biosimilars
Novel Biologics
Branded Formulations
Businesses
Overview
Generics
Executive Leadership Team
API
Generic Formulations
Quality & Compliance
Manufacturing Operations
Research & Development
Regulatory Affairs
Biosimilars
Biocon Biologics
Executive Leadership Team
Global Portfolio
Wide Global Footprint
Quality & Compliance
Partners
Global Scale Manufacturing
Research & Development
Branded Formulations
Novel Biologics
Biocon and Novels
Novels in Pipeline
Research Services
Investors
Overview
Financial Fact Sheet
Financial Information
Annual Reports
Quarterly Reports
Key Figures (Annual & Quarterly)
Earnings Call Recordings
Earnings Call Transcripts
Subsidiary Financials
Investor Presentations
Corporate Governance
Overview
Board of Directors
Board Committees
Our Leadership
Corporate Structure
Company History & Milestones
Governance Documents & Policies
Share Information
Share Graph
Share Series
Share Price Look Up
Investment Calculator
Share Price Alerts
Fragulizer
Dividends
Unclaimed and Unpaid Dividend
IEPF
Shareholder Services
Annual General Meeting
Postal Ballot
Investor Feedback
Investor FAQ
Miscellaneous Communication
Financial Calendar
Stock Exchange Disclosures
Notice of Board Meeting
Investors Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements & Disclosures
Analyst Coverage
Code Of Conduct
Email Subscription Services
Investor Contact
Careers
Overview
Working With Us
Now Hiring
Functions
Our Culture
Diversity And Inclusion
Learning & Development
Awards & Recognition
Benefits
Meet Our Employees
Career FAQ’s
Responsibility
Overview
Biocon Foundation
Social Impact
Partners
Grant-in-Aid
Awards and Recognition
Sustainability
Safer Workplace
An Environment of Change
Environmental Clearance
EHS Certifications
Biocon Academy
News
Overview
Press Releases
Company Statements
Media Stories
Image Gallery
Video Gallery
Events & Calendar
Media Contacts
More+
Contact Us
Blog
For Patients
Biocon in Malaysia
Group Companies
Syngene
Biocon BIologics
Bicara
Biocon Academy
Biocon
/
Investor Relations
/
Stock Exchange Disclosures
/
Other Announcements & Disclosures
OTHER ANNOUNCEMENTS & DISCLOSURES
STOCK EXCHANGE DISCLOSURES
Notice of Board Meeting
Investor Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements and Disclosures
FY 2022 - 23
May-22
12-May
SEBI Listing Regulations – Disclosure of related party transactions for the half-year ended March 31. 2022
06-May
Q4 FY22 – Earnings Call Transcript
Apr-22
28-Apr
Q4 FY22 – Investor Presentation With Earnings Call Recording Link
28-Apr
Outcome of Board Meeting – Financial Results for the quarter and year ended March 31, 2022
FY 2021 - 22
Mar-22
11-Mar
Intimation regarding revision in rating under Regulation 30 of SEBI Listing Regulations. – Rating Letter from ICRA
09-Mar
Intimation regarding revision in rating under Regulation 30 of SEBI Listing Regulations. – Rating Letter from CRISIL
Feb-22
28-Feb
Investor Presentation on “Biocon Biologics to acquire Viatris’ Biosimilars Business”.
07-Feb
Biocon Pharma Limited receives U.S. FDA approval for its Posaconazole Delayed-Release tablets ANDA
Jan-22
20-Jan
Q3 FY22 – Investor Presentation
20-Jan
Outcome of the Board Meeting – Financial Results Q3 FY22 for the quarter and nine months ended December 31, 2021
03-Jan
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dec-21
02-Dec
Biocon Pharma Limited, a subsidiary of Biocon Limited, received approval of its ANDA for Mycophenolic Acid from the US FDA.
Nov-21
19-Nov
Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
04-Nov
Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
02-Nov
Q2 FY22 – Investor Presentation
Oct-21
21-Oct
Outcome of the Board Meeting – Financial Results for the quarter and half year ended September 30, 2021
04-Oct
Kiran Mazumdar Shaw’s Notification to Stock Exchanges
Sep-21
30-Sep
Query on announcement dated September 16, 2021, regarding merger of Covidshield Technologies Private Limited with, and into Biocon Biologics Limited.
July-21
24-July
Re-appointment of Directors and Auditors of the Company
24-July
Outcome of 43rd Annual General Meeting
24-July
Scrutinizer’s report and Voting Results of 43rd AGM
23-July
Change in Directorate of the Company.
22-July
Outcome of Board Meeting – Financial Results for the quarter ended June 30, 2021;
June-21
30-June
Corporate governance report for the quarter ended june 30, 2021
FY 2020 - 21
May-21
19-May
Investor Presentation – Q4 FY-21
03-May
Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for Disclosures.
Apr-21
28-Apr
Change in Key Managerial Personnel of the Company.
28-Apr
Allotment of equity shares to Biocon India Limited Employee Welfare Trust under Biocon Restricted Stock Unit Long Term Incentive Plan FY 2020-24.
28-Apr
Outcome of Board Meeting – Financial Results for the quarter and year ended March 31, 2021
24-Apr
Annual Secretarial Compliance Report
01-Apr
Investor Presentation – Q3 FY-21
Mar-21
19-Mar
Intimation for Incorporation of Wholly Owned Subsidiary Company
08-Mar
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’).
Jan-21
21-Jan
Outcome of Board Meeting – Financial Results Q3 FY21 for the quarter and nine months ended December 31, 2020
Dec-20
09-Dec
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)
Oct-20
22-Oct
Outcome of Board Meeting – Financial Results for the quarter and half year ended September 30, 2020
Sep-20
22-Sep
Appointment of Mr. Anupam Jindal as Chief Financial Officer and Step down of Mr. Indranil Sen as Interim CFO
03-Sep
Allotment of shares by BBIL to Tata Capital
Aug-20
21-Aug
Intimation pursuant to Regulation 30 of SEBI Listing Regulations, amendment in Memorandum of Association of the Company
Jul-20
25-Jul
Voting results and scrutinizers’ report of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’)
25-Jul
Proceedings of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’)
23-Jul
Outcome of the Board Meeting
02-Jul
Notice of 42nd Annual General Meeting and the Annual Report for the FY 2019-20.
May-20
14-May
Outcome of the Board Meeting
14-May
Appointment of Interim Chief Financial Officer (‘Interim CFO’) and Key Managerial Personnel of the Company
Jan-20
23-Jan
Outcome of the Board Meeting
ARCHIVES
FY: From April 1 – March 31
Know more
about us
>> Generics
>> Biocon Academy
>> Biocon Malaysia
NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION
Previous
Next
Close
Test Caption
Test Description goes like this